Pharmacological activity of bamifylline on lung anaphylaxis: in vitro studies.
Bamifylline, a 7-8 disubstituted theophylline derivative, reduces in a dose dependent way (1 x 10(-5) M, 1 x 10(-4) M and 1 x 10(-3) M) the release of histamine, TXB2 (measured also as TXA2-like material) and SRS-A (as LTD4-like material) during the immunological challenge of actively sensitized guinea-pig lungs perfused in vitro. Theophylline was significantly less potent than bamifylline and particularly, at the higher concentrations used (1 x 10(-3) M), bamifylline was 2.7 times more potent than theophylline in reducing the immunological release of histamine and 1.6 and 1.5 times more potent in inhibiting the production of TXB2 and SRS-A, respectively. These data suggest that the ability of the two xanthine derivatives to control the immunological release of histamine represents an important point in understanding the mechanism of their anti-anaphylactic activity.
Department of Pharmacology, Chemotherapy and Medical Toxicology, University of Milan, Italy.
F
F
Berti
F
F
Magni
G
G
Rossoni
S
S
Bongrani
P
P
Schiantarelli
D000707:Anaphylaxis / Q000503:physiopathology*; D000818:Animals; D001681:Biological Assay; D001993:Bronchodilator Agents / Q000494:pharmacology*; D006168:Guinea Pigs; D006636:Histamine Release; D066298:In Vitro Techniques; D008171:Lung Diseases / Q000503:physiopathology*; D008297:Male; D010477:Perfusion; D011863:Radioimmunoassay; D013189:SRS-A / Q000032:analysis; D013806:Theophylline / Q000031:analogs & derivatives* / Q000494:pharmacology; D013928:Thromboxane A2 / Q000032:analysis
D001993:Bronchodilator Agents; D013189:SRS-A; D013928:Thromboxane A2; D013806:Theophylline; C006683:bamifylline